Aggressive Lymphomas
News
Zanubrutinib receives breakthrough designation for MCL
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
Conference Coverage
Chidamide may be more effective in PTCL than previously thought
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...
From the Journals
Adding umbralisib to ibrutinib produced responses in MCL, CLL
The doublet regimen “is the first successful combination for two drugs targeting B-cell blockade.”
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Conference Coverage
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
News
Group proposes new grading systems for CRS, neurotoxicity
A group of experts has proposed new consensus definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity related to...
News
Risk of second cancers in Hodgkin lymphoma survivors
Survivors of childhood Hodgkin lymphoma (HL) have a 14-fold higher risk of second cancers compared to the general population, according to new...
Conference Coverage
Checkmate 436: Two-drug combo is ‘promising’ for PMBCL
SAN DIEGO – The early results suggest a high overall response to the drug combination.
Conference Coverage
ECHELON-2: BV-CHP boosts survival in PTCL
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News
CHMP recommends BV+AVD for Hodgkin lymphoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
Combo bests standard care in younger CLL patients
SAN DIEGO—In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger...